Temozolomide in combination with celecoxib in patients with advanced melanoma. A phase II study of the Hellenic Cooperative Oncology Group

Annals of Oncology

Volumn 17, Issue 12, 2006, Pages 1835-1841

  Gogas, H ^a   Polyzos, A ^a   Stavrinidis, I ^b   Frangia, K ^c   Tsoutsos, D ^d   Panagiotou, P ^d   Markopoulos, C ^a   Papadopoulos, O ^a   Pectasides, D ^e   Mantzourani, M ^a   Middleton, M ^f   Vaiopoulos, G ^a   Fountzilas, G ^g  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b SAINT SAVVAS HOSPITAL   (Greece)

^c SOTIRIA GENERAL HOSPITAL   (Greece)

^d G GENNIMATAS GENERAL HOSPITAL   (Greece)

^e UNIVERSITY OF ATHENS   (Greece)

^f UNIVERSITY OF OXFORD   (United Kingdom)

^g ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

Author keywords

Celecoxib; Metastatic melanoma; Temozolomide

Indexed keywords

ANTIEMETIC AGENT; CELECOXIB; ONDANSETRON; TEMOZOLOMIDE;

ADULT; AGED; ALLERGIC REACTION; ALOPECIA; ANEMIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ARTHRALGIA; ARTICLE; BLOOD TOXICITY; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONFIDENCE INTERVAL; CONSTIPATION; DISEASE COURSE; DRUG BIOAVAILABILITY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; DYSPEPSIA; EPITHELIUM TUMOR; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FEVER; HEART INFARCTION; HEARTBURN; HUMAN; IMMUNOHISTOCHEMISTRY; LEUKOPENIA; LIVER METASTASIS; LIVER TOXICITY; LYMPHOCYTOPENIA; MAJOR CLINICAL STUDY; MALE; MELANOMA; MULTIPLE CYCLE TREATMENT; MYALGIA; NAUSEA AND VOMITING; NEUROTOXICITY; NEUTROPENIA; PATIENT COMPLIANCE; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; STOMATITIS; SURVIVAL RATE; SURVIVAL TIME; THROMBOCYTOPENIA; TREATMENT RESPONSE; VOMITING;

EID: 33845368719     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdl311     Document Type: Article

References (32)

1. Danson S, Lorigan P, Arance A et al. Randomized phase II study of TMZ given every 8 hours or daily with either interferon alfa-2b or thalidomide in metastatic malignant melanoma. J Clin Oncol 2003; 21: 2551-2555.
2. Batch CM, Soong SJ, Gershenwald JE et al. Prognostic factors analysis of 17.600 melanoma patients: Validation of the American Joint Committee on Cancer Melanoma Staging System. J Clin Oncol 2001; 19: 3622-3634.
3. Atkins MB. The treatment of metastatic melanoma with chemotherapy and biologics. Curr Opin Oncol 1997; 9: 205-213.
4. Newlands ES, Blackledge GR, Slack JA et al. Phase I trial of the temozolomide (CCRG 81045:M&B 39831: NSC 362856). Br J Cancer 1992; 65: 287-291.
5. Bleehen NM, Newlands ES, Lee SM et al. Cancer research campaign phase II trial of temozolomide metastatic melanoma. J Clin Oncol 1995; 13: 910-913.
6. Bafaloukos D, Gogas H, Georgoulias V et al. Temozolomide in combination with docetaxel in patents with advanced melanoma: A phase II study of the Hellenic Cooperative Oncology Group. J Clin Oncol 2002; 20: 420-425.
7. Middleton MR, Grob JJ, Aaronson N et al. Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. J Clin Oncol 2000; 18: 158-166.
8. Denkert C, Kobel M, Berger S et al. Expression of cyclooxygenase 2 in human malignant melanoma. Cancer Res 2001; 61: 303-308.
9. Vogt T, McClelland M, Jung B et al, Progression and NSAID-induced apoptosis in malignant melanomas are independent of cyclooxygenase II, Melanoma Res 2001; 11: 587-599.
10. Steinbach G, Lych PM, Phillips RKS et al. The effect of celecoxib, a cyclooxygenase-2 inhibitor in familial adenomatous polyposis. N Engl J Med 2000; 342: 1946-1952.
11. Kaplan E, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-481.
12. Lentner C. Geigy Scientific Tables (Exact Confidence Limits for P). Geneva, Switzerland: Ciba-Geigy 1982; 89-102.
13. Cox D. Regression models and life tables (with discussion). J R Stat Soc B 1972; 34: 187-220.
14. Temodar [temozolomide] capsules [package insert]. Kenilworth, NJ: Schering Corp 1999.
15. Stupp R, Ostermann S, Leyvraz S et al. Cerebrospinal fluid levels of temozolomide as a surrogate marker for brain penetration. Proc Am Soc Clin Oncol 2001; 20: 59a (Abstr 232).
16. Abrey LE, Christodoulou C. Temozolomide for treating brain metastases. Semin Oncol 2001; 28: 34-42.
17. Hwu WJ, Krown SE, Panageas KS et al. Temozolomide plus thalidomide in patients with advanced melanoma: Results of a dose-finding trial. J Clin Oncol 2002; 20: 2610-2615.
18. Atkins MB, Gollob JA, Sosman JA et al. A phase II pilot trial of concurrent biochemotherapy with cisplatin, vinblastine, temozolomide, interleukin 2 and IFN-alpha 2B in patents with metastatic melanoma. Clin Cancer Res 2002; 8: 3075-3081.
19. Agarwala SS, Kirkwood JM. Temozolomide in combination with interferon a-2b in patents with metastatic melanoma: A phase I dose-escalation study. Cancer 2003; 97: 121-127.
20. Leahy KM, Omberg RL, Wang Y et al. Cyclooxygenase-2 inhibition by celecoxib reduces proliferation and induces apoptosis in angiogenic endothelial cells in vivo. Cancer Res 2002; 62: 625-631.
21. Thun MJ, Henley SJ, Patrono C. Nonsteroidal anti-inflammatory drugs as anticancer agents: Mechanistic, pharmacologic and clinical tissues. J Natl Cancer Inst 2002; 94: 252-266.
22. Dicker AP, Williams TL, Grant DS. Targeting angiogenic processes by combination rofecoxib and ionizing radiation. Am J Clin Oncol 2001; 24: 438-442.
23. Harris RE, Alshafie GA, Abou-Issa H et al. Chemoprevention of breast cancer in rats by celecoxib, a cyclooxygenase 2 inhibitor. Cancer Res 2000; 60: 2101-2103.
24. Konerding MA, Fait E, Gaumann A. 3D microvascular architecture of precancerous lesions and invasive carcinomas of the colon. Br J Cancer 2001; 84: 1354-1362.
25. Rueg C, Zaric J, Stupp R. Non steroidal anti-inflammatory drugs and COX-2 inhibitors as anti-cancer therapeutics: Hypes, hopes and reality. Ann Med 2003; 35: 476-487.
26. Wilson KS, Allan SJ. Clinical activity of celecoxib (CXB) in metastatic malignant melanoma (MMM). Proc Am Soc Clin Oncol 2005; 23: 723s (Abstr 7555).
27. Kaufmann R, Spieth K, Leiter U et al. Temozolomide in combination with interferon-alfa versus temozolomide alone in patients with advanced metastatic melanoma: A randomized, phase III, multicenter study from the Dermatologic Cooperative Oncology Group. J Clin Oncol 2005; 23: 9001-9007.
28. Bafaloukos D, Tsoutsos D, Kalofonos H. Temozolomide and cisplatin versus temozolomide in patients with advanced melanoma: A randomized phase II study of the Hellenic Cooperative Oncology Group. Ann Oncol 2005; 16: 950-957.
29. Paul MJ, Summers Y, Calvert H et al. Effect of temozolomide on central nervous system relapse in patients with advanced melanoma. Melanoma Res 2002; 12: 175-178.
30. de Gast GC, Batchelor D, Kersten MJ et al. Temozolomide followed by combined immunotherapy with GM-CSF, low-dose IL-2 and IFN alpha in patients with metastatic melanoma. Br J Cancer 2003; 88: 175-180.
31. Hwu WJ, Krown SE, Menell JH et al. Phase II study of temozolomide plus thalidomide for the treatment of metastatic melanoma. J Clin Oncol 2003; 21: 3351-3356.
32. Solomon SD, McMurray JJV, Pfeffer MA et al. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med 2005; 352: 1071-1080.